
Jovan Milosavljevic, MD, an endocrinologist at Montefiore Einstein, explains what is driving CGM growth, which patients to consider, and what continuous data adds.

Jovan Milosavljevic, MD, an endocrinologist at Montefiore Einstein, explains what is driving CGM growth, which patients to consider, and what continuous data adds.

Every clinician can prescribe or refer for PrEP. The faculty outline the education, team structures, and community outreach that build prescriber confidence, and explain why HIV prevention still matters in the treatment era.

A gap between perceived and actual risk, messaging that has not reached women, and long drive times to a prescriber all limit PrEP uptake. The faculty examine what sustains PrEP deserts and how to bridge them.

Pauline M. Maki, PhD, reviews early OPTION-VMS findings showing improvements in hot flash bother, work productivity, depression, and anxiety with fezolinetant (Veozah).

Pauline M. Maki, PhD, introduces OPTION-VMS and explains why real-world data are needed to test whether randomized trial findings for nonhormonal VMS therapy generalize to everyday patients.

Specialty care approaches shared decision-making differently, and the stakes extend beyond a single symptom. The panel closes this discussion by debating whether treating agitation can shift disease trajectory itself.

With two on-label options now available, the choice between them comes down to comorbidities, psychosis, and risk. The panel also examines how long-term care rating pressures complicate that decision in practice.

Anna Taddio, PhD, shares how the CARD system reduced vaccine pain and fear in schools, pharmacies, and mass clinics, and how results varied by age.

Confirming HIV-negative status before starting PrEP, and at every follow-up, protects against partial treatment and drug resistance. The faculty compare testing strategies across clinical and pharmacy settings.

Patients rarely ask about PrEP unless someone asks first. The faculty describe how primary care clinicians and community pharmacists can open the conversation with confidence and without judgment.

Anna Taddio, PhD, explains why the 2026 guideline on vaccine distress treats vaccine pain and fear as a safety issue and what primary care clinicians should know.

Longer follow-up and real-world claims data add context that pivotal trials alone cannot provide. The panel examines both, alongside how monitoring for response actually happens in daily practice.

A second on-label option carries its own distinct mechanism and its own trial history. The panel details how this antipsychotic therapy was studied and what its data actually show.

Bleeding fears, skipped doses, and cost leave many patients with atrial fibrillation unprotected from stroke. A cardiologist and vascular medicine specialist explains.

See how PrEP blocks HIV, who benefits most, and why access gaps hit women, youth, and the South—plus ways to close them.

Explore how retatrutide, amylin therapies, and oral agents could expand obesity treatment beyond semaglutide and tirzepatide.

Geoffrey Barnes, MD, on why a careful exam is the first line of detection and which 2 risk factors primary care clinicians can actually change.

Safety data, not just efficacy, determines how comfortable clinicians feel prescribing. The panel reviews the safety profile, dosing schedule, and drug interactions relevant to a newer agitation therapy.

Pivotal trial data can reshape when clinicians feel comfortable starting treatment. The panel walks through the short- and long-term study results behind a newer agitation therapy in detail.

Daniel Drucker, MD, discusses gastrointestinal effects, hydration, pregnancy planning, and unanswered long-term safety questions.

An endocrinologist discusses the importance of history, comorbidities, lifestyle care, and outcomes beyond weight loss when choosing obesity treatment.

Daniel Drucker, MD, who coauthored the recent Endocrine Society scientific statement on obesity medicines, discusses key takeaways for primary care physicians.

Two on-label options are not enough for every patient. The panel weighs the field's remaining unmet needs against the biological rationale behind a newer, non-antipsychotic approach to treatment.

Decades of off-label prescribing for agitation associated with dementia due to Alzheimer’s are colliding with new evidence and new regulation. The panel examines why practice has lagged behind the data, and what is now changing.

Joshua LaBaer, PhD, reviews a national study he led that linked pre-existing antimicrobial antibodies with subsequent COVID-19 vaccine response.

Mina Fam, MD, addresses common prostate cancer misconceptions involving symptoms, elevated PSA, biopsy, and active surveillance.

Mina Fam, MD, reviews risk-based PSA interpretation, prostate MRI, biomarkers, and targeted biopsy in the modern diagnostic pathway.

Rodica Di Lorenzo, MD, explains why new headaches, migraine with aura, estrogen exposure, smoking, and pregnancy matter in stroke assessment.

A urologist discusses how primary care clinicians can identify patients most likely to benefit from prostate cancer screening while limiting overdiagnosis.

Before any prescription is written, non-pharmacologic strategies and a structured framework guide the panel's approach to agitation, alongside a biological explanation for why redirection so often fails.